<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037023</url>
  </required_header>
  <id_info>
    <org_study_id>113946</org_study_id>
    <nct_id>NCT01037023</nct_id>
  </id_info>
  <brief_title>Regulatory Hycamtin(Oral) PMS</brief_title>
  <acronym>Hycamtin PMS</acronym>
  <official_title>An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of HYCAMTIN Administered in Korean Patients According to the Prescribing Information</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, open-label, single group, multicentric post-marketing surveillance to
      monitor the safety and effectiveness of Topotecan administered in Korean patients according
      to the prescribing information
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional, open-label, single group, multicentric post-marketing surveillance to
      monitor the safety and effectiveness of Topotecan administered in Korean patients according
      to the prescribing information

      Topotecan will be administered as described the prescribing information or by physician's
      decision.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Occurrence of adverse events after Topotecan administration</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unexpected adverse event or adverse drug reaction</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse event or adverse drug reation</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">92</enrollment>
  <condition>Lung Cancer, Small Cell</condition>
  <arm_group>
    <arm_group_label>Patients administrated Topotecan</arm_group_label>
    <description>There is only one group. This group includes patients administrated Topotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>patients administrated Topotecan according to the prescribing information</description>
    <arm_group_label>Patients administrated Topotecan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients administrated Topotecan at the site
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        All subjects must satisfy the following criteria.

          -  Subject who is under the indication to the prescribing information of oral Hycamtin.

          -  Subject who is treated with oral Hycamtin according to the judgement of her or his
             investigator.

        All subjects must not satisfy the following criteria.

        â€¢ Subject who is under the contraindication to the prescribing information of oral
        Hycamtin.

        As considering the characteristic of observational post marketing surveillance, the
        exclusion criteria is not strict. All investigators should prescribe oral Hycamtin
        according to prescribing information which approved in Korea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seongnam-si, Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PMS (post-marketing surveillance)</keyword>
  <keyword>Topotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

